大型卒中人群中的二级预防：一项关于患者购买推荐药物的研究。
Secondary prevention in a large stroke population: a study of patients' purchase of recommended drugs.
作者信息
Wettermark Björn, Persson Anna, von Euler Mia
出版信息
Stroke. 2008 Oct;39(10):2880-5. doi: 10.1161/STROKEAHA.107.513390. Epub 2008 Aug 7.
BACKGROUND AND PURPOSE
In this study, linked, anonymous data from The National Hospital Discharge Register and the Swedish Prescribed Drug Register were used for studying to what extent recommended drugs for secondary prevention after stroke and TIA were purchased by patients in the region of Stockholm, Sweden (2 million inhabitants).
METHODS
Data on purchased drugs for secondary stroke prevention during July 2005 to June 2006 by 17 902 patients >18 years discharged after stroke or TIA during the period 1997 to June 2005 were analyzed by age, gender, and year of discharge.
RESULTS
Antiplatelets and warfarin were purchased by 87% of all stroke and 83% of all TIA patients, antihypertensives by 74% and 70%, and lipid lowering drugs by 41% and 39%, respectively.
CONCLUSIONS
Time after discharge had only a minor influence on the proportion of patients purchasing the medicines.
背景与目的
在本研究中，来自瑞典国家医院出院登记册和瑞典处方药登记册的关联匿名数据被用于研究瑞典斯德哥尔摩地区（200万居民）中风和短暂性脑缺血发作（TIA）后二级预防推荐药物的购买情况。
方法
分析了1997年至2005年6月期间中风或TIA后出院的17902名18岁以上患者在2005年7月至2006年6月期间购买的二级中风预防药物数据，按年龄、性别和出院年份进行分析。
结果
所有中风患者中87%购买了抗血小板药物和华法林，所有TIA患者中83%购买了此类药物；高血压药物购买比例分别为74%和70%；降脂药物购买比例分别为41%和39%。
结论
出院后的时间对购买药物的患者比例影响较小。
Zotero 插件